Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Frazer Institute, Faculty of Medicine, University of Queensland, Brisbane, 4102, Australia.
Mol Cancer. 2023 Oct 6;22(1):168. doi: 10.1186/s12943-023-01854-3.
Skin cancer is a global threat to the healthcare system and is estimated to incline tremendously in the next 20 years, if not diagnosed at an early stage. Even though it is curable at an early stage, novel drug identification, clinical success, and drug resistance is another major challenge. To bridge the gap and bring effective treatment, it is important to understand the etiology of skin carcinoma, the mechanism of cell proliferation, factors affecting cell growth, and the mechanism of drug resistance. The current article focusses on understanding the structural diversity of skin cancers, treatments available till date including phytocompounds, chemotherapy, radiotherapy, photothermal therapy, surgery, combination therapy, molecular targets associated with cancer growth and metastasis, and special emphasis on nanotechnology-based approaches for downregulating the deleterious disease. A detailed analysis with respect to types of nanoparticles and their scope in overcoming multidrug resistance as well as associated clinical trials has been discussed.
皮肤癌是对医疗体系的全球性威胁，如果不在早期阶段诊断，预计在未来 20 年内会大幅增加。即使在早期阶段可以治愈，但新药物的识别、临床成功和耐药性仍然是另一个主要挑战。为了缩小差距并提供有效的治疗，了解皮肤癌的病因、细胞增殖的机制、影响细胞生长的因素以及耐药性的机制非常重要。本文重点关注理解皮肤癌的结构多样性、迄今为止可用的治疗方法，包括植物化合物、化疗、放疗、光热疗法、手术、联合治疗、与癌症生长和转移相关的分子靶点，以及特别强调基于纳米技术的方法来下调有害疾病。详细分析了各种类型的纳米粒子及其在克服多药耐药性方面的应用范围，并讨论了相关的临床试验。
